Los Angeles Capital Management & Equity Research Inc. boosted its stake in Insmed Incorporated (NASDAQ:INSM) by 11.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 82,680 shares of the biopharmaceutical company’s stock after acquiring an additional 8,400 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Insmed were worth $1,955,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Quantbot Technologies LP lifted its position in Insmed by 196.1% during the 1st quarter. Quantbot Technologies LP now owns 4,841 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 3,206 shares in the last quarter. SG Americas Securities LLC bought a new stake in Insmed during the 1st quarter worth about $116,000. Smith Asset Management Group LP bought a new stake in Insmed during the 1st quarter worth about $166,000. Summit Trail Advisors LLC bought a new stake in Insmed during the 1st quarter worth about $250,000. Finally, Xact Kapitalforvaltning AB lifted its position in Insmed by 86.9% during the 1st quarter. Xact Kapitalforvaltning AB now owns 15,481 shares of the biopharmaceutical company’s stock worth $349,000 after buying an additional 7,200 shares in the last quarter.
INSM has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $43.00 price target on shares of Insmed in a research report on Friday, August 3rd. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Wednesday, July 4th. BidaskClub raised shares of Insmed from a “hold” rating to a “buy” rating in a research report on Thursday, May 31st. JMP Securities cut shares of Insmed from an “outperform” rating to a “market perform” rating in a research report on Monday, August 6th. Finally, Goldman Sachs Group initiated coverage on shares of Insmed in a research report on Monday, July 23rd. They set a “neutral” rating and a $32.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $38.80.
Insmed stock opened at $21.02 on Wednesday. The stock has a market cap of $1.71 billion, a PE ratio of -7.27 and a beta of 1.07. Insmed Incorporated has a fifty-two week low of $11.69 and a fifty-two week high of $33.94. The company has a current ratio of 14.14, a quick ratio of 14.14 and a debt-to-equity ratio of 0.83.
Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.08) by $0.08. research analysts expect that Insmed Incorporated will post -4.06 EPS for the current fiscal year.
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
Featured Story: Fundamental Analysis – How It Helps Investors
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.